“Interim Analysis of Phase 2 Results for Cemiplimab in Patients With Metastatic Basal Cell Carcinoma (mBCC) Who Progressed on or Are Intolerant to Hedgehog Inhibitors (HHIs)”. SKIN The Journal of Cutaneous Medicine 5, no. 1 (January 1, 2021): s3. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/1155.